Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pioglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 14/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | RXRA | P19793 | 1/20 | 0.96 |
| ▸ | MPC2 | O95563 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pioglitazone SCHEMBL503083 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29364546 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29593116 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21844 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4121 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162440 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL23534417 | 0.98 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162192 | 0.98 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL676871 | 0.98 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1462535 | 0.98 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101327198-A | Thiazolidinedione metallic salt medicament enteric-coated formulation and preparation method thereof | CHONGQING UNIVERSITY OF MEDICA (CN) | 2008-12-24 | — | — | CN | claimed |
| CN-110934866-B | Use of sitagliptin carboxylic acids and related compounds | 深圳微芯生物科技股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-101531657-A | Dimethyldiguanide of the thiazolidinedione pharmaceutical, preparation method and use thereof | UNIV CHONGQING MEDICAL | 2009-09-16 | — | — | CN | disclosed |
| CN-101041659-A | Pioglitazone derivative and pharmaceutical composition thereof | TIANJIN INST PHARM RESEARCH (CN) | 2007-09-26 | — | — | CN | disclosed |
| US-20060089387-A1 | Stabilized pharmaceutical composition comprising antidiabetic agent | MAI DE LTD. | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089387-A1 | Stabilized pharmaceutical composition comprising antidiabetic agent | ME1, HMGCR, ME2 | PPARG 118/4885CYP3A4 537/4885RXRA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.